Sam Lee, Ph.D.
Interim Co-Chief Executive Officer and President
Dr. Sam Lee has over 25 years of anti-infective drug discovery research experience. Prior to Cocrystal, he managed anti-infective drug discovery projects for eight years at Icos Corporation (Nasdaq: ICOS). At Icos, Dr. Lee was responsible for incorporating protein crystallography and structural screening technologies into Icos research and played a key role for developing phosphoinositide 3-kinase (PI3K) delta inhibitors, which ultimately yielded an FDA approved product. He received his Ph.D. in Biological Sciences from the University of Notre Dame, and completed postdoctoral training in viral biochemistry with Dr. I. R. Lehman at Stanford University. While at Stanford, Dr. Lee founded and was CEO of Viral Assays in Cupertino, CA.
James J. Martin
Interim Co-Chief Executive Officer and Chief Financial Officer
Mr. James Martin has over 25 years of finance and management experience including providing financial leadership to commercial-stage, publicly traded health science companies. Prior to Cocrystal, Mr. Martin served as the Chief Financial Officer of Motus GI (Nasdaq: MOTS), a medical device company. From September 2014 to November 2016 he served as the Chief Financial Officer of VBI Vaccines, Inc. (formerly SciVac Therapeutics, Inc.) (Nasdaq: VBIV), a pharmaceutical development and manufacturing company. From April 2014 to September 2015, Mr. Martin served as Chief Financial Officer of Vapor Corp, Inc. (Nasdaq: VPCO), a vaporizer retail and wholesale company. From January 2011 to October 2013, Mr. Martin served as Chief Financial Officer of SafeStitch prior to its merger with TransEnterix, Inc. (NYSE: TRXC). Mr. Martin also serves as the Chief Financial Officer of Non-Invasive Monitoring Systems, Inc. (OTC Pink: NIMU), a company marketing non-invasive medical devices. Mr. Martin holds an undergraduate degree in business administration and an MBA from Barry University in Miami. He is a Certified Public Accountant.